Sanofi-Pasteur begins development of a new generation of anti-rabies products
-
Last Update: 2020-07-04
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Sanofi-Pasteur has announced that it will jointly develop a new generation of rabies-resistant biodeficiency products, the anti-rabies monoclonal antibodies, for use in conjunction with the rabies vaccine for post-exposure prevention of rabies, a deadlydiseaseIt is understood that rabies once the onset of disease, the fatality rate is very highTherefore, the dog and other mammals seriously bitten, must use active and passive immunity two means to preventActive immunity refers to rabies vaccination, passive immunity refers to the injection of rabies immunoglobulinAs a new biological product, rabies monoclonal antibodies have the potential to replace rabies immunoglobulins currently in useCrucell has successfully developed rabies bioproducts made from two monoclonal antibodiesPreclinical studies and Phase I clinical trials have shown that this product is more effective than the immunoglobulin currently in use and can quickly neutralize rabies virus(Zhang Xiao)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
